𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis

✍ Scribed by Hillel S. Panitch; Ronald A. Thisted; Richard A. Smith; Daniel R. Wynn; James P. Wymer; Anat Achiron; Timothy L. Vollmer; Raul N. Mandler; Dennis W. Dietrich; Malcolm Fletcher; Laura E. Pope; James E. Berg; Ariel Miller

Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
194 KB
Volume
59
Category
Article
ISSN
0364-5134

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Rituximab in patients with primary progr
Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial
✍ Kathleen Hawker; Paul O'Connor; Mark S. Freedman; Peter A. Calabresi; Jack Antel πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 158 KB πŸ‘ 2 views

## Abstract ## Objective Rituximab, a monoclonal antibody selectively depleting CD20+ B cells, has demonstrated efficacy in reducing disease activity in relapsing‐remitting multiple sclerosis (MS). We evaluated rituximab in adults with primary progressive MS (PPMS) through 96 weeks and safety thro

Magnetic resonance imaging results of th
Magnetic resonance imaging results of the PRISMS trial: A randomized, double-blind, placebo-controlled study of interferon-Ξ²1a in relapsing-remitting multiple sclerosis
✍ David K. B. Li; Donald W. Paty πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 164 KB πŸ‘ 2 views

The PRISMS (Prevention of Relapses and Disability by Interferon-␀1a Subcutaneously in Multiple Sclerosis) trial was a doubleblind, randomized, multicenter, phase III, placebo-controlled study of interferon-␀1a in 560 patients from 22 centers in 9 countries with clinically definite or laboratory-supp